diabetestalk.net

Animas Vibe Discontinued

Animas Insulin Pumps Are Being Discontinued And “users Must Be Supported”

Animas Insulin Pumps Are Being Discontinued And “users Must Be Supported”

Diabetes care company Animas is to close down. This means that in the long term, Animas Vibe insulin pumps will no longer be available. The sale of all Animas Vibe and OneTouch Ping insulin pumps has been discontinued with immediate effect in the US and Canada. For Europe and the UK this process, which will see Animas ceasing operation and sale of pumps, will take much longer. Johnson & Johnson, the firm behind Animas, said on 5 October 2017 that Animas pumps and products will continue to be available through healthcare providers and for sale as normal in the UK for an as yet unconfirmed but limited period of time. Johnson & Johnson will provide further information for UK Animas pump users, including what their options are for using different pumps, in due course. The firm has also said Animas will continue to provide customer service, training and warranty support, including providing pump supplies that are used with the Animas Vibe, during a limited ‘transition period’. The length of time this will be available has yet to be confirmed. Other Johnson & Johnson Diabetes Care companies, including blood glucose monitoring focused Lifescan, which includes OneTouch branded products, and Calibra, producers of an insulin patch pump, are not included in this change. Karen Addington, UK Chief Executive of JDRF said: “This news is concerning and JDRF is monitoring the situation. Users of these particular insulin pumps must not be negatively affected in any way. They should be supported by Animas and their healthcare team to move smoothly on to alternative pumps.” If you have any questions about how this might affect you please call Animas Patient Support on 0800 055 6606 in the UK or 1800 812 715 in Republic of Ireland. Continue reading >>

Johnson & Johnson's Animas To Shut Down Ops And Exit Insulin Pump Biz, 410 Jobs Affected

Johnson & Johnson's Animas To Shut Down Ops And Exit Insulin Pump Biz, 410 Jobs Affected

October 5, 2017 By Alex Keown, BioSpace.com Breaking News Staff CHESTERBROOK, Pa. – Animas Corporation, a Johnson & Johnson division focused on diabetes care, is exiting the space and shutting down operations and laying off 410 employees. This morning, Pennsylvania-based Animas Corporation will discontinue the manufacturing and sale of the insulin pumps it manufactures, Animas Vibe and One-Touch Ping. The two pumps are used by approximately 90,000 diabetes patients. In a statement issued this morning, Animas said patients using its products will be allowed to transition their needs to rival company Medtronic plc . Animas said it will continue to provide customer service, training and warranty support to insulin-pump customers through a transition period, although how long that period will be was not disclosed. Johnson & Johnson announced earlier this year that it was exploring strategic options to maximize shareholder value and one of those was the possible sale of its diabetes care business. In January, J&J said it planned to seek a possible sale, joint venture or operating partnerships for LifeScan Inc., Animas and Calibra Medical Inc.. as part of a plan to spark growth. This morning, Johnson & Johnson said it will continue to evaluate potential strategic options for LifeScan, Inc. and its blood glucose monitoring OneTouch brand of products. In its statement announcing the close of Animas, the company said the decision to shutter Animas was due to the changing needs of customers, market dynamics and increased competition. The combination of challenges made it “too difficult to sustain the insulin pump business” and the decision was made to close down Animas. Animas is moving quickly with its decision. As of today, the company has discontinued sales of its insuli Continue reading >>

Solara Medical Supplies

Solara Medical Supplies

Flexible Spending Account (FSA) Eligible Products? This product is FSA Approved which means that is typically eligible for purchase using a Flexible Spending Account. FSA coverage can vary from plan to plan, and your individual employer ultimately determines which products and services are eligible for coverage. Please refer to your employer or plan for the exact details of your flexible spending account before using it. It's here to help you perform at your best. This CGM-enabled Animas Vibe insulin pump combines high-performance pumping with state-of-the-art sensing. It's designed to streamline the whole CGM (continuous glucose monitoring) experience for you, while giving you a continuous, accurate view of how your glucose is behaving. It shows you your glucose in full-on, colour-coded action. Animas Vibe insulin pump is the first and only Dexcom G4 PLATINUM CGM-enabled insulin pump to have a high-contrast colour screen. It delivers rich information, too. Coloured trend arrows and lines show where your glucose is heading and how fast, so you can consider this information, along with the results of fingerstick testing, to help guide therapy adjustments. We keep our eye on the insulin thats active. Our Insulin on Board feature tracks the insulin still active in your body to help prevent hypoglycaemia due to stacking (making additional insulin unnecessarily). Continue reading >>

Animas Pumps Discontinued

Animas Pumps Discontinued

WRITTEN BY: Michelle Boise Editor’s Note: This announcement affects customers in the US and Canadian markets only. CHESTERBROOK, Pa., – Johnson & Johnson’s Diabetes Care Company, Animas Corporation has announced the intended discontinuation of manufacturing The Animas® Vibe® and OneTouch Ping® insulin pumps. Animas Corporation has pledged to continue customer support and training, as well as provide warranty for the pump supplies associated with the discontinued devices for a period of time. Through Sept. 30, 2019, Medtronic will provide Animas supplies to those who continue using these insulin pumps. Animas Corporation has pledged to continue customer support and training, as well as provide warranty for the pump supplies associated with the discontinued devices for a period of time. Currently, only US and Canadian customers are affected. Details still to be released regarding how this will impact those in Australia, New Zealand and international markets. Valerie Asbury, General Manager of Animas Corporation, made a statement to current pump users, saying, “We recognize that patients living with diabetes rely on our products to provide critical care, and we want to reassure them that we will be with them every step of the way throughout this transition.” While current Animas users will have support to transition to Medtronic at no cost (avoiding the threat of losing a pump altogether or fighting with insurance providers for coverage), the move leaves many in the US and Canadian diabetes community uneasy. Just earlier this year, Roche discontinued its Accu-Chek® insulin pump, leaving one less device option for people with Type 1 diabetes in an already small pump market. Roche also directed customers to Medtronic. For many with Type 1 who depend on insulin Continue reading >>

Johnson & Johnson Unit Exits Insulin Pump Business Amid Rising Competition

Johnson & Johnson Unit Exits Insulin Pump Business Amid Rising Competition

(Reuters) - Johnson & Johnson’s diabetes care unit, which makes insulin pumps, said on Thursday it would shut its business in United States and Canada amid increased competition and after failing to find a buyer. Animas Corp has selected rival Medtronic Plc as its partner for the device and nearly 90,000 patients using its pumps will be offered the option to transfer to pumps made by Medtronic. J&J has been reviewing strategic options, including a potential sale of its diabetes care division, which includes LifeScan Inc, Animas Corp and Calibra Medical Inc. The division reported sales of $421 million in the second quarter, down 10.6 percent from a year earlier. Analysts said Animas’ exit from the insulin pump business is not surprising. “Animas has not been investing in its product pipeline or aggressively adding patients to its platform over the last year,” William Blair analyst Margaret Kaczor said in a client note. Animas would continue to sell its insulin pumps - Animas Vibe and OneTouch Ping - outside of the United States and Canada, J&J spokeswoman Bridget Doherty told Reuters on Thursday. Brokerage JP Morgan said device makers Medtronic, Insulet Corp and Tandem Diabetes Care Inc could benefit from J&J’s exit from the insulin pump business. However, DexCom Inc, which partnered with Animas, could lose both new and existing blood-glucose monitoring patients, JPMorgan analysts said in a note. Animas said its parent continues to evaluate potential strategic options for blood glucose monitoring business, LifeScan Inc. Shares of J&J and DexCom were marginally down in early morning trading while shares of Medtronic, Insulet and Tandem rose. Continue reading >>

After Ceasing Animas Insulin Pump Sales In U.s., Canada, J&j To Lay Off 297

After Ceasing Animas Insulin Pump Sales In U.s., Canada, J&j To Lay Off 297

Earlier this month, Johnson & Johnson announced it would stop manufacturing and selling its Animas insulin pumps in the U.S. and Canada, effective immediately. Now, a WARN notice shows, the company will lay off 297 employees in Pennsylvania. The layoffs, effective Dec. 15, will affect employees at Johnson & Johnson sites in West Chester and Wayne, according to the Pennsylvania WARN notice. Animas employs about 410 people globally, about half of whom work at its Chesterbrook site in Wayne and a manufacturing facility in West Chester, according to The Philadelphia Inquirer. The Chesterbrook site also houses J&J’s LifeScan unit and its Diabetes Institute. "Animas has discontinued the sale of all Animas Vibe and OneTouch Ping insulin pumps in the U.S. and Canada, effective immediately. A decision and timing to exit countries outside of the U.S. and Canada is subject to completing consultation with relevant works councils. For the patients, caregivers and healthcare providers outside of the U.S. and Canada who currently use Animas pumps and products, Animas will continue to sell pumps and operate as usual," said Bridget Kimmel, a J&J spokeswoman, in an email. The company partnered with Medtronic to offer Animas pump users the opportunity to transfer to a new device. Soon after J&J’s announcement, Insulet offered a free trial of its tubeless, “pod-based” insulin pump to Animas users. And this week, Insulet teamed up with Dexcom to provide its Omnipod system along with a $200 gift card toward Dexcom’s G5 Mobile continuous glucose monitor. RELATED: J&J alerts patients to insulin pump cybersecurity flaws, but says risk is low J&J acquired Animas in 2005 for $518 million. The insulin pump business along with LifeScan, which makes blood glucose monitors, and Calibra Medi Continue reading >>

Animas Shutting Down: What You Need To Know

Animas Shutting Down: What You Need To Know

Animas announced on October 5, 2017 that it is exiting the insulin pump business immediately and will no longer make and sell it’s Animas Vibe and OneTouch Ping insulin pumps. For current users, Animas will continue to have customer service for existing users of their pumps and provide warranty support. They will honor warranties and will continue providing the supplies used with their pumps. Who Is Affected? Current Animas customers in the US and Canada are affected by this announcement. Nothing is changing for patients using Animas pumps in other parts of the world (i.e., outside of the US and Canada). What If I Have an Animas Pump and I’m Under Warranty? If you are on a pump with a warranty that expires on or after September 30, 2019, you or your pump supplier will be contacted by a member of the Medtronic transition team concerning the option to transfer to a Medtronic 630G insulin delivery system at no cost. If your warranty expires before September 30, 2019, Animas will continue to honor your warranty until your warranty expires and you transition to a new pump. What If I Have an Animas Pump and I’m Not Under Warranty? If your pump is not under warranty or your pump has a warranty expiring by December 31, 2017, you may explore your options as you normally would by consulting with your diabetes care team and insurance company to select a new insulin pump, if needed. Can I Still Order Animas Supplies? Yes, Animas will continue to provide supplies to Animas pump users. What Other Insulin Pumps Are Available? Animas is partnering with Medtronic to transition patients (medtronicdiabetes.com/Animas). Though, please note that people with diabetes should consult with their medical team to make decisions about what insulin pump to transition to. You shouldn’t be fo Continue reading >>

Animas To Discontinue Manufacturing And Sale Of Insulin Pumps

Animas To Discontinue Manufacturing And Sale Of Insulin Pumps

Animas Corporation has announced that it will discontinue the manufacturing and sale of Animas® Vibe® and OneTouch Ping® insulin pumps, close operations and exit the insulin pump business. Animas has selected Medtronic as its partner-of-choice to facilitate a seamless transition for patients, caregivers and healthcare providers. Patients using an Animas insulin pump will be offered the option to transfer to a Medtronic pump. Patient safety and continuity of care is of utmost importance and Animas will continue to provide customer service, training and warranty support, including providing pump supplies that are used in conjunction with the Animas® Vibe® and OneTouch Ping® insulin pumps, through a transition period. “We recognize that patients living with diabetes rely on our products to provide critical care, and we want to reassure them that we will be with them every step of the way throughout this transition,” said Valerie Asbury, General Manager of Animas Corporation. “Our number one priority is ensuring patients have a seamless experience as they transition to Medtronic. For over 30 years, Medtronic has been a global leader in the treatment of those living with diabetes, and we are confident they will provide outstanding support to our patients and their healthcare teams.” “We are incredibly grateful to our patients and healthcare partners for the trust, confidence and loyalty they have placed in Animas products over the last 12 years,” Asbury said. “With changing needs of customers, rapidly evolving market dynamics, and increased competitive pressures, it proved too difficult to sustain the insulin pump business and we decided to pursue an exit of the business. This decision was extremely difficult and comes following the extensive exploration Continue reading >>

Animas Shuts Down Its Pump Line

Animas Shuts Down Its Pump Line

Johnson & Johnson has decided to disconnect from the insulin pump market, a move that will leave Animas, Animas Vibe, and OneTouch Ping users looking for a new pump. A press release by the company said it has partnered with Medtronic to transition its existing customers to Medtronic’s pump line. Johnson & Johnson representatives cited increased competition as the reason the Animas brand has being discontinued. This news was first reported in the diabetes news sphere by Diabetes Mine on its Facebook page. sponsor The move to pull the plug on the Animas pump brand has long been seen as a possibility by market watchers, but outwardly Johnson & Johnson has professed a “business as usual” attitude with customers. When Diabetic Investor blogger David Kliff wrote about the possibility of consolidation in the insulin pump market in a February 2017 Diabetic Connect article, the company responded to the article by saying, “Animas continues to manufacture, deliver and support its products and provide the service our patients expect. We remain committed to our patients, and we intend to honor our warranty and do not anticipate any interruptions to patients’ pump therapy. If patients or potential patients have any concerns, they can contact Animas online or at 1-877-YES-PUMP.” That number’s phone tree now prompts customers to learn more about the decision to shudder the Animas pump line. I called the number and was connected with a call center operator who read a prepared statement about the transition. It said that customers whose warranties expire on or after September 30th, 2019 will have the option to transition to a Medtronic 630G free of charge; this Medtronic pump automatically suspends insulin delivery should the system’s CGM detect that blood glucose levels Continue reading >>

Animas Corporation

Animas Corporation

Animas Corporation is an American company that specializes in making insulin pumps, used by people with diabetes. The company was founded by Dr. Katherine Crothall in 1996, had its initial public offering in May 2004 under the ticker symbol 'PUMP', and was ultimately acquired by Johnson & Johnson on February 18, 2006. The business is headquartered in West Chester, Pennsylvania and forms part of the Johnson & Johnson Diabetes franchise along with Lifescan and several other companies producing medical products for the treatment and management of diabetes. On October 5, 2017 Johnson & Johnson's Animas Corporation announced that they are closing down their operations in the insulin pump market and had sold their customer database to (“partnered with”) Medtronic [1]. Their press release: Johnson & Johnson's Animas Corp. said Thursday it plans to close operations and exit the insulin pump business. The company will discontinue the manufacturing and sale of its Animas, Vibe and OneTouch Ping insulin pumps. Animas said Medtronic PLC (mdt) will help facilitate a transition for the 90,000 patients who use Animas pumps, and who will be offered the option to transfer to a Medtronic pump. Animas employs 410 people around the world. The move comes as part of J&J's strategic review announced in January, in which it is continuing to evaluate options for LifeScan, a blood glucose monitoring company with the OneTouch brand of products. Animas 2020[edit] The Animas 2020 is an insulin pump that carries 200 units of insulin and can be connected to an infusion set following the Luer standard. Its predecessor was the Animas IR1250. The pump comes in five different colors, features a color screen and allows the user to have custom alarm tones. To improve treatment the system can save instr Continue reading >>

Here For You.

Here For You.

Animas recently announced it has discontinued sales of its pumps in the United States and Canada and will close its pump business. As Animas’ partner-of-choice for this transition, our Medtronic team is ready to help. We know that when it comes to your diabetes management needs, it’s a very personal decision and our experienced team is here to support you through every step in the process. Over the past 30 years, we have set out to transform diabetes care to enable greater freedom and better health through innovations across the care continuum, through advanced pump and CGM therapies, and comprehensive services like our StartRight Program and 24-hour Helpline that has served over 1.2 million people in more than 100 countries worldwide to date. In fact, our unparalleled service is the #1 reason our customers stay with us. Guided by our Medtronic Mission, we continually strive to address unmet needs through best-in-class solutions for people with diabetes around the world. Stay Connected We make it easy for our customers to stay connected with us and others in the Diabetes Online Community. Through our social channels, we share helpful diabetes tips, stories and perspectives from the community as well as from our Medtronic team. We count on our robust online community to give us feedback and help shape the solutions we innovate to help transform diabetes care so we invite you to join the conversation and stay connected with us! If you need pump supplies or customer support for your current Animas pump, you can continue to use the same methods you do today – nothing changes for now. As always, an Animas team member can be reached at 877-937-7867 (US) and 866-406-4844 (Canada). If your pump warranty has expired, you’re at risk of going off therapy should something h Continue reading >>

Newsflash: Animas Exiting Insulin Pump Market

Newsflash: Animas Exiting Insulin Pump Market

After nearly two decades, the Johnson & Johnson-owned Animas brand of insulin pumps is shutting down. In the early morning hours on Thursday (Oct. 5), J&J issued a press release that finalized nine months of speculation on the future of its diabetes insulin pump division. Effective immediately, no more Animas pumps will be sold in the USA or Canada, and it's TBD what will happen to the brand internationally. Pharma giant J&J has been "strategically evaluating" its three diabetes divisions since January, deciding whether to prop them up financially, sell them off, or shut them down. While many have speculated that an end was near for Animas and possibly even J&J's OneTouch and Lifescan meter brands, nothing has been official until now. The meter brands remain under evaluation, but its pump business is done and J&J has signed an agreement with competitor and market leader Medtronic to take over servicing existing Animas customers. On the heels of Roche also shutting its insulin pump business in January, what this Animas announcement means is that for the first time since 2002, we PWDs (people with diabetes) in the U.S. will have just three choices of pumps: Medtronic Minimed, Insulet's Omnipod and the Tandem t:slim. Total bummer, given that Animas has been a staple in the industry for 17 years and was well-liked for its waterproof design and Animas Vibe system paired with the Dexcom CGM. Animas Shutdown: Nuts and Bolts Here are answers to some of the biggest questions: How Many? This affects 90,000 existing Animas pump customers, according to the J&J news release (although other sources quote 120,000). We asked how many employees are impacted, but the company declined to release specifics except to generally say, "We will continue to operate certain functions of the busin Continue reading >>

Animas To Cease Sale Of Insulin Pumps

Animas To Cease Sale Of Insulin Pumps

Animas Corporation, a Johnson & Johnson Diabetes Care company, announced it will discontinue the manufacturing and sale of its insulin pumps and close operations, exiting the insulin pump market, according to a company press release. Animas will partner with Medtronic to transfer its patients using the Animas Vibe and OneTouch Ping insulin pumps to a Medtronic pump. “We are incredibly grateful to our patients and health care partners for the trust, confidence and loyalty they have placed in Animas products over the last 12 years,” Valerie Asbury, general manager of Animas, said in the release. “With changing needs of customers, rapidly evolving market dynamics and increased competitive pressures, it proved too difficult to sustain the insulin pump business, and we decided to pursue an exit of the business. This decision was extremely difficult and comes following the extensive exploration of all other viable options for the Animas business.” About 90,000 people with diabetes are currently using Animas pumps. Patients, caregivers and health care providers can find more information at www.medtronicdiabtes.com/Animas. Continue reading >>

Animas Corporation To Close Operations And Exit Insulin Pump Market

Animas Corporation To Close Operations And Exit Insulin Pump Market

Animas Corporation to Close Operations and Exit Insulin Pump Market Company will work with Medtronic as a partner-of-choice to help ensure a smooth transition for patients on insulin pumps CHESTERBROOK, Pa., Oct. 5, 2017 /CNW/ --Animas Corporation, one of the Johnson & Johnson Diabetes Care Companies, today announced that it intends to discontinue the manufacturing and sale of Animas Vibe and OneTouch Ping insulin pumps, close operations and exit the insulin pump business. Animas has selected Medtronic plc (NYSE: MDT), a world leader in diabetes, as its partner-of-choice to facilitate a seamless transition for patients, caregivers and healthcare providers. Patients using an Animas insulin pump will be offered the option to transfer to a Medtronic pump. Patient safety and continuity of care is of utmost importance and Animas will continue to provide customer service, training and warranty support, including providing pump supplies that are used in conjunction with the Animas Vibe and OneTouch Ping insulin pumps, through a transition period. "We recognize that patients living with diabetes rely on our products to provide critical care, and we want to reassure them that we will be with them every step of the way throughout this transition," said Valerie Asbury, General Manager of Animas Corporation. "Our number one priority is ensuring patients have a seamless experience as they transition to Medtronic. For over 30 years, Medtronic has been a global leader in the treatment of those living with diabetes, and we are confident they will provide outstanding support to our patients and their healthcare teams." "We are incredibly grateful to our patients and healthcare partners for the trust, confidence and loyalty they have placed in Animas products over the last 12 years," As Continue reading >>

Newsflash: Roche Stops Selling Accu-chek Insulin Pumps In U.s.

Newsflash: Roche Stops Selling Accu-chek Insulin Pumps In U.s.

If you were hoping to buy a new Accu-Chek brand insulin pump from Roche Diabetes Care anytime soon, you're unfortunately out of luck. There's now one less player in the pump market, as the diabetes device company that makes the popular Accu-Chek brand of meters, test strips and insulin pumps has made the decision to stop selling pumps here in the United States -- at least for now. We learned about this when a CDE contacted us after an Accu-Chek rep apparently told her that Roche had "dropped out of the U.S. pump market," and this educator was surprised not to find any details on the company website. "This is not the way other pump companies have handled ceasing operations... and I wondered why. Do you have any back story?" she wrote us. Reaching out to Roche, spokeswoman Anne Gill confirmed that the company is not accepting any new pump customers as of Dec. 31, 2016, and explained: "At the end of the year, Roche Diabetes Care did re-prioritize our efforts in the U.S. with regards to our IDS (insulin delivery system) business. We are no longer proactively upgrading or acquiring new pump patients on our current system. Instead, we are concentrating our efforts on servicing our current Accu-Chek Spirit and Accu-Chek Combo patients." What Went Wrong? When we pressed for more detail, Gill shifted into marketing mode, saying how excited the company is about its new Accu-Chek Guide glucose monitor that was just FDA-approved last Fall and will go on sale this year. By not selling new pumps, she said, the company can focus on the launch for this Accu-Chek Guide system... wow, really?! It's a bit unclear whether this is a permenent decision, given that Gill tells us the company remains committed to bringing an array of "new innovations" here to the U.S. "This decision will not ha Continue reading >>

More in diabetes